AltraBio is an R&D company for analysis and interpretation of biomedical data in both preclinical and clinical development and for development of analytic and predictive tools. AltraBio is particularly focused on OMICS technologies (genomics, transcriptomics, proteomics etc.) and flow/mass cytometry with the goal of unlocking the value captured in large scale data set generated in life science experimental studies. AltraBio's work flow covers the part of the R&D process following the generation of data in the experiment. This includes extensive data quality control, normalization, statistical analysis (using nonsupervised and supervised approaches) and their management, visualization and extensive exploration. In contrast to a pure biostatistics consultancy, AltraBio performs a full-fledged biological interpretation of the analysis results in the context of current biomedical knowledge and generates a report that includes deep bibliography review and biological pathway analysis. AltraBio applies the state-of-the-art knowledge in biomedicine and bioinformatics to inform both development of informatics tools used in its work and the analysis and interpretation of the experimental data sets. Also, AltraBio has developed a proprietary tool for the automation of the tedious manual gating in cytometry approaches. This machine learning approach allows the application of a predetermined gating strategy while saving study time/cost and enhancing robustness. The use of this technique is helpful for studies with a high number of samples to treat one by one during a long time or in a batch process and its compatibility with GcLP allows its use in clinical trials.